In a report released today, Doug Schenkel from Cowen & Co. maintained a Hold rating on NanoString Tech (NSTG), with a price target of $14. The company’s shares closed yesterday at $15.09.
According to TipRanks.com, Schenkel is a top 100 analyst with an average return of 26.4% and a 70.9% success rate. Schenkel covers the Healthcare sector, focusing on stocks such as Pacific Biosciences, Guardant Health Inc, and Exact Sciences.
NanoString Tech has an analyst consensus of Moderate Buy, with a price target consensus of $18.60.
See today’s analyst top recommended stocks >>
Based on NanoString Tech’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.6 million. In comparison, last year the company had a GAAP net loss of $11.4 million.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NSTG in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NanoString Technologies, Inc. engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway.
